Vigabatrin vs placebo: 50% or greater reduction in seizure frequency
Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Vigabatrin vs placebo ≥ 50% reduction in seizure frequency (ITT analysis) Duration of treatment (range): 16–36 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy Vigabatrin may leads to higher ≥ 50% reduction in seizure frequency (ITT analysis) Duration of… compared with placebo (low certainty). Vigabatrin add‐on therapy for drug‐resistant focal epilepsy (2020) · Cochrane Headline outcomes only | RR 2.6 [1.87, 3.63] | 4 studies · 513 participants | Low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Vigabatrin add‐on therapy for drug‐resistant focal epilepsy 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.